

of mammalian cell in vivo or ex vivo.

92 ~~23~~. (Amended) [The antibody of claim ~~2~~<sup>3</sup>, wherein said] A monoclonal antibody which (a) binds to a soluble extracellular domain sequence of an Apo-2 polypeptide which [comprises] consists of amino acids 1 to 182 of SEQ ID NO:1 and (b) stimulates apoptosis in at least one type of mammalian cell in vivo or ex vivo.

Sub D  
24. (Amended) A monoclonal antibody which binds to a soluble polypeptide [comprising] which is (a) an extracellular domain sequence of [a native sequence] Apo-2 polypeptide which [comprises] consists of amino acids 54 to 182 of SEQ ID NO:1 or (b) a fragment of (a) which binds Apo-2 ligand, is immunogenic, or is capable of modulating apoptosis in a mammalian cell.

C1  
C19  
C19  
25. (Amended) The monoclonal antibody of claim ~~21~~<sup>1</sup> or ~~24~~<sup>14</sup>, wherein said antibody is a chimeric antibody.

20 ~~26~~. (Amended) The monoclonal antibody of claim ~~21~~<sup>1</sup> or ~~24~~<sup>14</sup>, wherein said antibody is a humanized antibody.

Sub C  
E1  
2 ~~27~~. (Amended) A homodimeric molecule comprising any two antibodies of claims ~~8~~<sup>21</sup>, ~~10~~<sup>23</sup>, [19,] ~~21~~<sup>1</sup>, ~~22~~<sup>3</sup> or ~~24~~<sup>14</sup>.

2 Please add the following claims:

~~29~~. The monoclonal antibody of claim ~~21~~<sup>1</sup> which is a human antibody.

5 ~~31~~. The monoclonal antibody of claim ~~22~~<sup>4</sup> which is a human antibody.

C3 ~~32~~. The monoclonal antibody of claim ~~23~~<sup>9</sup> which is a human antibody.

16 ~~33~~. The monoclonal antibody of claim ~~24~~<sup>14</sup> which is a human antibody.

6 ~~34~~. The monoclonal antibody of claim ~~22~~<sup>4</sup> which is a chimeric antibody.